Ace the CRNI Challenge 2026 – Infuse Your Career with Success!

The correct answer is focused on assessing the patient's renal function and blood counts prior to the administration of cisplatin, a chemotherapy drug known for its nephrotoxic potential. Conducting a complete blood count (CBC) helps to evaluate the levels of red blood cells, white blood cells, and platelets, which is important because cisplatin can lead to myelosuppression. It is also critical to measure blood urea nitrogen (BUN) and creatinine to assess renal function. Since cisplatin is primarily excreted by the kidneys, ensuring that the patient has adequate renal function helps in determining if the drug can be safely administered without risking acute kidney injury.

While vitamin levels and liver function tests, electrolyte levels, and imaging studies (like X-rays or MRIs) can provide valuable health information, they are not specifically relevant to the immediate assessment of the patient’s suitability for cisplatin treatment. Vitamin and liver evaluations do not directly address the primary risks associated with cisplatin, and imaging studies would not provide the necessary information regarding hematological and renal parameters that are critical for patient safety before chemotherapy.